Ratings by Wolfe Research (Rudy Li)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/15/2026 | Ovid Therapeutics Inc | OVID | New Coverage | Outperform (N/A) |
2.19 (2.15) |
-1.83% | Details | |
| 10/15/2026 | Bright Minds Biosciences Inc. | DRUG | New Coverage | Outperform (N/A) |
50.71 (51.30) |
1.16% | Details | |
| 10/15/2026 | Rapport Therapeutics | RAPP | New Coverage | Outperform (N/A) |
28.33 (27.57) |
-2.68% | Details | |
| 8/26/2026 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Outperform (N/A) |
38.95 (37.95) |
-2.57% | Details | |
| 7/29/2026 | uniQure BV | QURE | Upgrade | Outperform (Peerperform) |
36.66 (21.78) |
-40.59% | Details | |
| 7/27/2026 | MapLight Therapeutics | MPLT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | LB Pharmaceuticals Inc | LBRX | New Coverage | Outperform (N/A) |
33.41 (36.74) |
9.97% | Details | |
| 5/22/2026 | Alto Neuroscience | ANRO | New Coverage | Outperform (N/A) |
21.54 (21.94) |
1.86% | Details | |
| 5/22/2026 | Compass Pathways | CMPS | New Coverage | Outperform (N/A) |
11.59 (10.75) |
-7.25% | Details | |
| 5/22/2026 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
12.30 (6.97) |
-43.33% | Details | |
| 3/31/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Peerperform (Outperform) |
27.58 (40.50) |
46.85% | Details | |
| 2/24/2026 | uniQure BV | QURE | New Coverage | Peerperform (N/A) |
23.43 (36.66) |
56.47% | Details | |
| 2/24/2026 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
34.29 (24.17) |
-29.51% | Details | |
| 2/24/2026 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
42.23 (33.49) |
-20.7% | Details | |
| 2/24/2026 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
183.72 (157.14) |
-14.47% | Details | |
| 2/24/2026 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
128.63 (135.71) |
5.5% | Details | |
| 2/24/2026 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Outperform (N/A) |
335.28 (241.76) |
-27.89% | Details | |
| 2/24/2026 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
23.99 (19.12) |
-20.3% | Details | |
| 2/24/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Peerperform (N/A) |
20.19 (17.61) |
-12.78% | Details | |
| 2/24/2026 | Alkermes | ALKS | New Coverage | Outperform (N/A) |
31.91 (41.22) |
29.18% | Details | |
| 2/24/2026 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
24.50 (27.58) |
12.57% | Details | |
| 2/23/2026 | Definium Therapeutics Inc | DFTX | New Coverage | Outperform (N/A) |
17.13 (32.10) |
87.39% | Details |
